IMMray PanCan-d highlighted in meeting arranged by Pancreatic Cancer Action Network
LUND, Sweden, April 16, 2021 /PRNewswire/ Immunovia s bloodtest IMMray PanCan-d was mentioned in the seminar The latest in early detection for pancreatic cancer arranged by Pancreatic Cancer Action Network (pancan.org) on April 15, 2021.
Dr. Rosalie Sears, professor in the department of molecular and medical genetics at Oregon Health and Science University, expressed her enthusiasm for Immunovias bloodtest and the test performance. She was especially impressed by the fact that a non-invasive bloodtest can be used to detect early stages I and II of pancreatic cancer which is crucial for improving treatment outcomes in pancreatic cancer care.
Share this article
LUND, Sweden, April 16, 2021 /PRNewswire/
Immunovia s bloodtest IMMray™ PanCan-d was mentioned in the seminar The latest in early detection for pancreatic cancer arranged by Pancreatic Cancer Action Network (pancan.org) on April 15, 2021.
Dr. Rosalie Sears, professor in the department of molecular and medical genetics at Oregon Health and Science University, expressed her enthusiasm for Immunovias bloodtest and the test performance. She was especially impressed by the fact that a non-invasive bloodtest can be used to detect early stages I and II of pancreatic cancer which is crucial for improving treatment outcomes in pancreatic cancer care.
Oregon Health and Science University is one out of 23 centers participating in Immunovia s study PanFAM-1, one of the largest prospective studies to date focusing on early diagnosis in high-risk individuals with Familial/Hereditary Pancreatic Cancer (FPC).
Share this article
Share this article
LUND, Sweden, Feb. 15, 2021 /PRNewswire/ According to the American Cancer Society, as many as 10% of pancreatic cancers are caused by familial and hereditary risk factors. PanFAM-1 is the largest prospective study to date, focusing on early diagnosis in high-risk individuals with Familial/Hereditary Pancreatic Cancer (FPC). Designed to support the road to reimbursement for Immunovia s blood test, IMMray™ PanCan-d, the study has ended enrollment of new subjects October 30, 2020 from the 23 familial/hereditary pancreatic cancer high-risk surveillance programs in USA and Europe. The study reports the collection of over 3000 blood samples from 1265 subjects. The last blood samples will be collected in April 2021. All blood samples will be analysed in the second half of 2021.